Medicaid expands podiatric care; Medicare clarifies diabetic shoe coverage

What it does

This bill expands Medicaid coverage to include podiatric physicians (doctors of podiatric medicine) as recognized physicians under the program, allowing their services to be reimbursed starting January 1, 2026. It also clarifies Medicare's rules for covering therapeutic diabetic shoes by requiring physician documentation of specific foot conditions and diabetes management, effective January 1, 2028, and adds a conforming amendment to anti-kickback statute safe harbors.

Why we flagged it

The bill's operative mechanism is to expand Medicaid and Medicare coverage for podiatric services and diabetic footwear by clarifying eligibility and documentation standards. It is a straightforward healthcare access measure, not a tax provision, appropriation, or deregulation.

What the text implies

• Podiatric physicians may see significant revenue increase from Medicaid reimbursement, creating a financial beneficiary class not explicitly named in the bill's civic framing.
• The conforming amendment to Section 1877(h)(6) (anti-kickback statute safe harbor) may create new referral pathways between physicians and shoe suppliers; the scope of this safe harbor is not detailed in the bill text and depends on Secretary rulemaking.
• State implementation timelines vary: states with 2-year legislatures get extended compliance windows, potentially creating unequal access to podiatric services across states during the transition period.
• Medicare shoe coverage now requires physician attestation rather than podiatrist or orthotist attestation alone, potentially creating a bottleneck if physicians are unfamiliar with diabetic foot pathology documentation standards.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Diabetic patients and Medicaid beneficiaries gain expanded access to podiatric care and therapeutic shoes with clearer documentation standards. Podiatric physicians gain reimbursement eligibility, but the primary civic effect is improved access to foot and ankle care for vulnerable populations (diabetics, low-income beneficiaries) who face high amputation risk.

Who stands to gain

• podiatric physicians
• shoe manufacturers and suppliers (pedorthists, orthotists)
• medical device/orthotic companies

Named in the bill

Medicaid (Title XIX, Social Security Act), Medicare (Title XVIII, Social Security Act), podiatric physicians, Secretary of Health and Human Services, State legislatures, pedorthists, orthotists

Where it stands

61 cosponsors: 40 Democrats, 21 Republicans.

• Mar 12, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 12, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $240,000 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

John Joyce, the sponsor, reported $1,473,437 in PAC receipts in the 2026 cycle.

• Alliance for Aging Research — $140,000 on 2 filings
• American Podiatric Medical Association — $100,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.